Biological Assembly 1  

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 77.29 kDa 
• Atom Count: 4,865 
• Modelled Residue Count: 563 
• Deposited Residue Count: 696 
• Unique protein chains: 1

 6BQ0

Structure of human monoacylglycerol lipase bound to a covalent inhibitor

• PDB DOI:  https://doi.org/10.2210/pdb6BQ0/pdb

• Classification: Hydrolase/Hydrolase Inhibitor
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 
• Membrane Protein: Yes  OPM


• Deposited: 2017-11-27 Released: 2018-03-14 
• Deposition Author(s): Pandit, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.214 
• R-Value Work: 0.179 
• R-Value Observed: 0.180 

Literature

Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.

McAllister, L.A., Butler, C.R., Mente, S., O'Neil, S.V., Fonseca, K.R., Piro, J.R., Cianfrogna, J.A., Foley, T.L., Gilbert, A.M., Harris, A.R., Helal, C.J., Johnson, D.S., Montgomery, J.I., Nason, D.M., Noell, S., Pandit, J., Rogers, B.N., Samad, T.A., Shaffer, C.L., da Silva, R.G., Uccello, D.P., Webb, D., Brodney, M.A.

(2018) J Med Chem 61: 3008-3026

• PubMed: 29498843 
• DOI: https://doi.org/10.1021/acs.jmedchem.8b00070
• Primary Citation of Related Structures:  
  6BQ0


• PubMed Abstract: 
  

Monoacylglycerol lipase (MAGL) inhibition provides a potential treatment approach to neuroinflammation through modulation of both the endocannabinoid pathway and arachidonoyl signaling in the central nervous system (CNS). Herein we report the discovery of compound 15 (PF-06795071), a potent and selective covalent MAGL inhibitor, featuring a novel trifluoromethyl glycol leaving group that confers significant physicochemical property improvements as compared with earlier inhibitor series with more lipophilic leaving groups. The design strategy focused on identifying an optimized leaving group that delivers MAGL potency, serine hydrolase selectivity, and CNS exposure while simultaneously reducing log  D, improving solubility, and minimizing chemical lability. Compound 15 achieves excellent CNS exposure, extended 2-AG elevation effect in vivo, and decreased brain inflammatory markers in response to an inflammatory challenge.

---

Organizational Affiliation: 

Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoglyceride lipase	A, B	348	Homo sapiens	Mutation(s): 0  Gene Names: MGLL EC: 3.1.1.23 Membrane Entity: Yes
UniProt & NIH Common Fund Data Resources
Find proteins for Q99685 (Homo sapiens) Explore Q99685  Go to UniProtKB:  Q99685
PHAROS:  Q99685

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
E3A (Subject of Investigation/LOI)	C [auth A], D [auth B]	1-({(1R,5S,6r)-6-[1-(4-fluorophenyl)-1H-pyrazol-3-yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl}oxy)pyrrolidine-2,5-dione C19 H17 F N4 O4 FNIBKVOGYHDUDM-UOIKSKOESA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.214 
• R-Value Work: 0.179 
• R-Value Observed: 0.180 
• Space Group: I 2 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 86.31	α = 90
b = 126.62	β = 90
c = 138.06	γ = 90

Software Package:

Software Name	Purpose
HKL-2000	data scaling
BUSTER	refinement
PDB_EXTRACT	data extraction
HKL-2000	data reduction
BUSTER	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2018-03-14 
Deposition Author(s): Pandit, J.

Revision History  

• Version 1.0: 2018-03-14
  Type: Initial release
  
• Version 1.1: 2018-04-25
  Changes: Data collection, Database references